pharma · Hypophosphatasia · Paroxysmal Nocturnal Hemoglobinuria
Alexion Europe SAS
Alexion Pharma Germany is a pharma organization headquartered in EU. Primary therapeutic focus areas include Hypophosphatasia, Paroxysmal Nocturnal Hemoglobinuria, Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)
EU HQ
89 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- EU
- Employees
- 89
- Programs
- 33
- Drugs
- 40
- Patents
- 0
ALXN 2040, Placebo matching ALXN2040
Phase 2 · small molecule · Geographic atrophy (GA) secondary to Age-related Macular Degeneration (AMD)
ALXN 2040, Placebo matching ALXN2040 for Geographic atrophy (GA) secondary to Age-related Macular Degeneration (AMD) is a Phase 2 program (small_molecule) at Alexion Europe SAS with 1 ClinicalTrials.gov record(s).
Internal code ALXN2040-GA-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Alexion Europe SAS
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Geographic atrophy (GA) secondary to Age-related Macular Degeneration (AMD)
- Status
- active
- Trials
- 1